clinical trial · NCT05683496
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
ACELYRIN Inc.·phase2·completed·n = 31
Thyroid Eye DiseaselonigutamabPlacebo
brief summary
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
started
Feb 14, 2023
primary completion
May 26, 2025
completion
May 26, 2025
last updated
Jul 1, 2025
official title
A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol